Astria Therapeutics (NASDAQ:ATXS) Upgraded at Citizens Jmp

Astria Therapeutics (NASDAQ:ATXS) was upgraded by equities research analysts at Citizens Jmp to a “strong-buy” rating in a report issued on Friday,Zacks.com reports.

Several other research analysts have also issued reports on ATXS. JMP Securities started coverage on Astria Therapeutics in a research report on Friday. They issued an “outperform” rating and a $26.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Thursday, January 23rd. Finally, Oppenheimer lifted their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $25.67.

Astria Therapeutics Price Performance

NASDAQ ATXS opened at $7.86 on Friday. The firm has a market capitalization of $443.54 million, a price-to-earnings ratio of -3.76 and a beta of 0.70. Astria Therapeutics has a 52-week low of $7.16 and a 52-week high of $16.90. The company has a 50 day simple moving average of $8.93 and a 200-day simple moving average of $10.45.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ATXS. Dimensional Fund Advisors LP increased its holdings in shares of Astria Therapeutics by 1,043.7% in the second quarter. Dimensional Fund Advisors LP now owns 146,158 shares of the biotechnology company’s stock valued at $1,330,000 after purchasing an additional 133,379 shares during the period. Hsbc Holdings PLC purchased a new position in shares of Astria Therapeutics during the second quarter worth $171,000. Millennium Management LLC grew its position in shares of Astria Therapeutics by 13.5% during the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after buying an additional 218,518 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Astria Therapeutics during the second quarter worth about $2,561,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Astria Therapeutics during the third quarter worth approximately $155,000. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.